Tariff recovery real, but core profit remains thin

The ₹7.12 crore reported profit looks strong on the headline—a 153% jump year-on-year. But dig into other income and the picture inverts. Of ₹7.11 crore in other income, ₹3.73 crore is unrealized fair value and FX gains—non-recurring mark-to-market swings that won't repeat. Strip those out and core PAT runs closer to ₹3-4 crore. That's not disappointing; it's a reset to reality. The actual story sits one line up: operating profit, a 12-fold jump to ₹3.43 crore on flat revenue. No accounting massage there. That's genuine operational recovery from tariff stress.

Q1 FY26 was brutal for Meenakshi. US tariffs clobbered margins and operating profit collapsed to ₹0.28 crore. Management's response was surgical: share tariff burden with customers, time shipments to favorable tariff windows, tighten cost of materials, and shift geographic mix away from tariff-hit channels. In Q1 FY27, volumes are still flat (revenue ₹32.24 crore, down 3.4% YoY), and US share dropped from 50% to 40%. But the operational levers worked. Cost of materials fell to 45.6% of revenue from 48% prior year. Operating leverage kicked in despite flat volumes. That 12-fold operating profit jump is not inflation; it's proof that tariff stress has begun to ease and management's margin defense held.

Flat revenue and a 3.4% core EBITDA margin are not destinations—they are way-stations. US revenue share fell from 50% to 40% due to tariff drag and customer overstocking. Europe now accounts for ~60%, a shift that may be structural (China Plus One is real) or temporary (if tariffs reverse, US will rebound). Management disclosed that this quarter reflects 'a blend of tariff and overstocking,' not yet a recovery in order flow. Translation: the tailwind hasn't materialized in customer bookings yet.

Management outlined a phased capacity expansion: ₹40–50 crore over FY27–FY30 (₹20 crore per factory), first facility by FY28, second by FY30. They also revealed tariff-hedging contingencies—a Sri Lanka contract manufacturing MOU and exploratory work in Nepal and Vietnam. On the negative side, D2C ambition (SHORTSTOP brand) is paused due to patent dispute; test marketing never got off the ground. Guidance was reaffirmed (FY30: ₹500 crore revenue, ₹65 crore PAT, ~15% CAGR), but management conceded that FTA upside is unquantified and dependent on external operationalization (EU Q1 CY27, US ongoing).

The stock popped 4.61% on the day of the result and held steady through day 5 (+5.33%), a signal that the market read the quarter as fundamentally positive despite the reported-vs.-core gap. However, institutional positioning is hollow. FII ownership sits at 0%, DII at 0%, promoter at 72.39%—no institutional accumulation visible. The move appears retail-driven or short covering, not conviction buying. This matters: without DII/FII inflows, the pop could fade if tariff headlines darken or guidance gets cut. Watch for institutional interest to build only when FY28 margin guidance (17% EBITDA target) becomes more concrete or when China Plus One orders materialize in customer announcements.